Poddubnaya, Irina V.
| Issue | Section | Title | Abstract | File |
| Vol 21, No 4 (2019) | CLINICAL ONCOLOGY | The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution | Abstract |
 (Rus) |
| Vol 22, No 1 (2020) | CLINICAL ONCOLOGY | Solitary (extramedullary) plasmocytoma. Clinical recommendations | Abstract |
(Rus) |
| Vol 22, No 1 (2020) | CLINICAL ONCOLOGY | ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution | Abstract |
(Rus) |
| Vol 22, No 1 (2020) | CLINICAL ONCOLOGY | Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer | Abstract |
(Rus) |
| Vol 22, No 2 (2020) | Conference Proceedings | Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic | Abstract |
(Rus) |
| Vol 22, No 2 (2020) | Original Article | Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 | Abstract |
(Rus) |
| Vol 22, No 2 (2020) | Conference Proceedings | New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas | Abstract |
(Rus) |
| Vol 22, No 2 (2020) | Review | Accompanying therapy in oncohematological patients with secondary immunodeficiency | Abstract |
(Rus) |
| Vol 22, No 2 (2020) | Best Practice | Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience | Abstract |
(Rus) (Eng) |
| Vol 22, No 2 (2020) | Original Article | First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice | Abstract |
(Rus) |
| Vol 22, No 4 (2020) | CLINICAL ONCOLOGY | Multiple myeloma | Abstract |
(Rus) |
| Vol 22, No 4 (2020) | CLINICAL ONCOLOGY | The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review | Abstract |
(Rus) |
| Vol 22, No 4 (2020) | CLINICAL ONCOLOGY | Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy | Abstract |
(Rus) |